Jaguar Health, Inc. (JAGX): Price and Financial Metrics

Jaguar Health, Inc. (JAGX)

Today's Latest Price: $0.20 USD

0.02 (-8.64%)

Updated Oct 30 4:00pm

Add JAGX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 364 in Miscellaneous

See all "A" rated Strong Buy stocks

JAGX Stock Summary

  • Jaguar Health Inc's market capitalization of $16,033,621 is ahead of merely 7.4% of US-listed equities.
  • Jaguar Health Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 88.99% of US listed stocks.
  • With a year-over-year growth in debt of -20.13%, Jaguar Health Inc's debt growth rate surpasses merely 14.01% of about US stocks.
  • Stocks that are quantitatively similar to JAGX, based on their financial statements, market capitalization, and price volatility, are LEAF, RPD, CSOD, QUOT, and WK.
  • Visit JAGX's SEC page to see the company's official filings. To visit the company's web site, go to

JAGX Stock Price Chart Interactive Chart >

Price chart for JAGX

JAGX Price/Volume Stats

Current price $0.20 52-week high $1.22
Prev. close $0.22 52-week low $0.19
Day low $0.19 Volume 3,339,700
Day high $0.22 Avg. volume 3,454,426
50-day MA $0.33 Dividend yield N/A
200-day MA $0.51 Market Cap 16.03M

JAGX Latest News Stream

Event/Time News Detail
Loading, please wait...

JAGX Latest Social Stream

Loading social stream, please wait...

View Full JAGX Social Stream

Latest JAGX News From Around the Web

Below are the latest news stories about Jaguar Health Inc that investors may wish to consider to help them evaluate JAGX as an investment opportunity.

Jaguar Health sells Mytesi royalties for $5M

Jaguar Health (JAGX) inks an agreement an unnamed secured lender to sell royalty rights related to future sales of antidiarrheal med Mytesi (crofelemer), certain upfront license fees and milestone payments for $5M.Contingent on mutual agreement, additional royalty financings of $5M in February 2021 and $6M in July 2021 may be instituted.Net...

Seeking Alpha | October 1, 2020

'Psyched': Compass IPO, UC Berkeley's Psychedelics Center, Jaguar Health's Entheogen Initiative

Compass IPO Begins Trading on NASDAQ Following a NASDAQ filing earlier this month, UK-based psychedelics research company Compass Pathways began …

Benzinga | September 20, 2020

Jaguar Health amends receivable deal with Oasis Capital, shares +30% premarket

Jaguar Health (JAGX) and its subsidiary, Napo Pharmaceuticals, have jointly entered into a third amendment to the accounts receivable purchase agreement with Oasis Capital dated May 12, 2020.Pursuant to agreement, Oasis to purchase additional accounts receivable of the Company related to the sales of the Company’s Mytesi drug product to...

Seeking Alpha | September 10, 2020

The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...

Benzinga | September 4, 2020

Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea

A significant proportion of patients undergoing cancer therapy experience diarrheaSAN FRANCISCO, CA / ACCESSWIRE / August 6, 2020 / Jaguar Health, Inc.

Yahoo Finance | August 6, 2020

Read More 'JAGX' Stories Here

JAGX Price Returns

1-mo -34.02%
3-mo -69.41%
6-mo -56.80%
1-year -72.66%
3-year -99.90%
5-year -99.99%
YTD -75.03%
2019 -95.00%
2018 -89.10%
2017 -80.56%
2016 -68.00%
2015 N/A

Continue Researching JAGX

Here are a few links from around the web to help you further your research on Jaguar Health Inc's stock as an investment opportunity:

Jaguar Health Inc (JAGX) Stock Price | Nasdaq
Jaguar Health Inc (JAGX) Stock Quote, History and News - Yahoo Finance
Jaguar Health Inc (JAGX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8106 seconds.